Celularity Inc. Class A Common Stock

Day range

$0.75 – $1.00

Open

$0.96

Prev close

$0.98

Volume

185.52K

Market cap

$31.73M

Shares out

32.45M

P/E

—

P/S

1.70

P/B

-0.90

P/FCF

—

ROE

130.3%

ROA

-48.1%

Debt/Equity

-1.06

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentSep 29, 2026

  On September 29, 2026, the Board of Directors (the "Board") of Celularity Inc. (the "Company") appointed Naveen Jain to serve as a member of the Board, with his term to commence upon the expiration of the applicable waiting period following the filing and mailing of an Information Statement pursuant to Section 14(f) of the Securities Exchange Act of 1934, as amended, and Rule 14f-1 promulgated thereunder (the "Effective Time"). Mr. Jain was designated for appointment to the Board pursuant to the board designation rights granted to certain investors in connection with the Company's previously announced September 2026 financing.

• Debt retirementSep 28, 2026

  Upon issuance of the 700,000 shares, the Exchange Note was permanently satisfied and cancelled, Helena's related security interests and liens were released, and Helena waived the remaining $200,000 of installment payments under the parties' prior settlement agreement.

• Listing compliance regainedSep 14, 2026

  On September 11, 2026, Celularity Inc. received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that Celularity has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). Nasdaq has advised Celularity that each of these matters is now closed.

• Executive officer departureAug 7, 2026

  On August 5, 2026, Celularity Inc. (the "Company") terminated the employment of Rick Gonzalez, the Company's Chief Commercial Officer, effective immediately. As of such date, Mr. Gonzalez ceased serving as the Company's Chief Commercial Officer.

• Listing deficiency noticeJul 29, 2026

  On July 23, 2026, Celularity Inc. (the "Company") received notice from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5450(a)(1) because the closing bid price for the Company's Class A common stock has fallen below $1.00 per share for the last 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until January 19, 2027, to regain compliance with the minimum bid price requirement.

Days to cover

2.5

Short interest

391.28K

Avg volume

154.93K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Celularity Provides Update Regarding Nasdaq Listing Compliance
  negativeGlobeNewswire Inc.· Aug 25, 2026
• Celularity Receives Nasdaq Notice Regarding Form 10-Q
  negativeGlobeNewswire Inc.· May 29, 2026
• EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
  positiveBenzinga· Mar 10, 2026
• Celularity Receives Nasdaq Notice Regarding Form 10-Q
  negativeGlobeNewswire Inc.· Aug 22, 2025
• Celularity Receives Nasdaq Notice Regarding Form 10-Q
  neutralGlobeNewswire Inc.· May 30, 2025